Literature DB >> 32376571

[Effect of heat inactivation of blood samples on the efficacy of three detection methods of SARS-CoV-2 antibodies].

Xiongyan Xue1, Changlin Zhu1, Shaozhen Huang1, Lianhua Pan1, Jianhua Xu2, Weixuan Li1.   

Abstract

OBJECTIVE: To evaluate the effects of heat inactivation of blood samples at 56℃ for 30 min on the results of SARS-CoV-2 antibody detection using different methods.
METHODS: This retrospective study was conducted in 11 patients with established diagnosis of COVID-19 and 10 patients with diseases other than COVID- 19 in our hospital. We collected samples of serum, plasma and whole blood from each patient between February, 12 and 18, 2020, and with a double- blind design, the samples were examined for SARS-CoV-2 antibodies before and after heat inactivation at 56 ℃ for 30 min. In all the samples, the total SARS-CoV-2 antibodies were detected using immunochromatography, and the IgM antibodies were detected using fluorescence immunochromatography; the IgM and IgG antibodies in the serum and plasma samples detected with chemiluminescence immunoassay. We compared the detection results and analyzed the correlation of semi-quantitative detection results of IgM and IgG antibodies before and after heat inactivation of the samples.
RESULTS: With immuno-chromatography, the coincidence rate of the total SARS-CoV-2 antibody detection before and after heat inactivation of the serum and plasma samples was 90.0% in COVID-19 cases and 100.0% in the negative cases, resulting in a total coincidence rate 95.2%; for the whole blood samples, the total coincidence rates of the total SARS-CoV-2 antibodies were 100.0%. For detection of IgM antibodies in the serum, plasma and whole blood samples using fluorescence immunochromatography, the coincidence rates in SARS-CoV-2-positive and negative cases and the total coincidence rate before and after inactivation were 100.0%, 0 and 47.6%, respectively. For detection of serum IgM and IgG antibodies and plasma IgG antibodies with chemiluminescence immunoassay, the coincidence rates in SARS-CoV-2-positive and negative cases and the total coincidence rate before and after inactivation were all 100.0%, and the total coincidence rate of plasma IgM antibodies was 95.2%. Pearson correlation analysis of the semi-quantitative results of IgM and IgG detection in the serum and plasma samples showed a correlation coefficient of 0.9999 (95%CI: 0.9998-1.000, P < 0.001) between the results before and after sample inactivation.
CONCLUSIONS: Heat inactivation of blood samples at 56 ℃ for 30 min does not obviously affect the results of immunochromatography and chemiluminescent immunoassay for detection of SARS-COV-2 antibodies but can reduce the risk of infection for the operators. Heat-inactivated samples can not be used in fluorescence immunochromatography for SARS-CoV-2 antibody detection.

Entities:  

Keywords:  SARS-CoV-2; antibodies; heat inactivation; plasma; serum

Mesh:

Substances:

Year:  2020        PMID: 32376571      PMCID: PMC7167315          DOI: 10.12122/j.issn.1673-4254.2020.03.03

Source DB:  PubMed          Journal:  Nan Fang Yi Ke Da Xue Xue Bao        ISSN: 1673-4254


  6 in total

1.  [Expert consensus on the use of corticosteroid in patients with 2019-nCoV pneumonia].

Authors:  J P Zhao; Y Hu; R H Du; Z S Chen; Y Jin; M Zhou; J Zhang; J M Qu; B Cao
Journal:  Zhonghua Jie He He Hu Xi Za Zhi       Date:  2020-02-08

2.  Molecular Diagnosis of a Novel Coronavirus (2019-nCoV) Causing an Outbreak of Pneumonia.

Authors:  Daniel K W Chu; Yang Pan; Samuel M S Cheng; Kenrie P Y Hui; Pavithra Krishnan; Yingzhi Liu; Daisy Y M Ng; Carrie K C Wan; Peng Yang; Quanyi Wang; Malik Peiris; Leo L M Poon
Journal:  Clin Chem       Date:  2020-04-01       Impact factor: 8.327

3.  Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR.

Authors:  Victor M Corman; Olfert Landt; Marco Kaiser; Richard Molenkamp; Adam Meijer; Daniel Kw Chu; Tobias Bleicker; Sebastian Brünink; Julia Schneider; Marie Luisa Schmidt; Daphne Gjc Mulders; Bart L Haagmans; Bas van der Veer; Sharon van den Brink; Lisa Wijsman; Gabriel Goderski; Jean-Louis Romette; Joanna Ellis; Maria Zambon; Malik Peiris; Herman Goossens; Chantal Reusken; Marion Pg Koopmans; Christian Drosten
Journal:  Euro Surveill       Date:  2020-01

4.  The Extent of Transmission of Novel Coronavirus in Wuhan, China, 2020.

Authors:  Hiroshi Nishiura; Sung-Mok Jung; Natalie M Linton; Ryo Kinoshita; Yichi Yang; Katsuma Hayashi; Tetsuro Kobayashi; Baoyin Yuan; Andrei R Akhmetzhanov
Journal:  J Clin Med       Date:  2020-01-24       Impact factor: 4.241

Review 5.  The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis.

Authors:  John Mair-Jenkins; Maria Saavedra-Campos; J Kenneth Baillie; Paul Cleary; Fu-Meng Khaw; Wei Shen Lim; Sophia Makki; Kevin D Rooney; Jonathan S Nguyen-Van-Tam; Charles R Beck
Journal:  J Infect Dis       Date:  2014-07-16       Impact factor: 5.226

6.  The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China.

Authors:  David S Hui; Esam I Azhar; Tariq A Madani; Francine Ntoumi; Richard Kock; Osman Dar; Giuseppe Ippolito; Timothy D Mchugh; Ziad A Memish; Christian Drosten; Alimuddin Zumla; Eskild Petersen
Journal:  Int J Infect Dis       Date:  2020-01-14       Impact factor: 3.623

  6 in total
  3 in total

1.  Comparison of Five Serological Assays for the Detection of SARS-CoV-2 Antibodies.

Authors:  Anja Dörschug; Julian Schwanbeck; Andreas Hahn; Anke Hillebrecht; Sabine Blaschke; Kemal Mese; Uwe Groß; Sascha Dierks; Hagen Frickmann; Andreas E Zautner
Journal:  Diagnostics (Basel)       Date:  2021-01-06

2.  Preliminary Analysis of B- and T-Cell Responses to SARS-CoV-2.

Authors:  Li-Xia Zhang; Shu-Yan Miao; Zhong-Hua Qin; Jun-Pin Wu; Huai-Yong Chen; Hai-Bai Sun; Yi Xie; Yan-Qing Du; Jun Shen
Journal:  Mol Diagn Ther       Date:  2020-10       Impact factor: 4.476

3.  A high-throughput Anti-SARS-CoV-2 IgG testing platform for COVID-19.

Authors:  Jinwei Du; Eric Chu; Dayu Zhang; Chuanyi M Lu; Aiguo Zhang; Michael Y Sha
Journal:  J Virol Methods       Date:  2020-11-02       Impact factor: 2.014

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.